The Fort Worth Press - Frenchman rewarded for lifetime of research into narcolepsy

USD -
AED 3.672504
AFN 65.000368
ALL 81.431326
AMD 361.239406
ANG 1.789785
AOA 918.000367
ARS 1544.046724
AUD 1.452222
AWG 1.8
AZN 1.70397
BAM 1.754002
BBD 2.018116
BDT 124.801578
BGN 1.747831
BHD 0.378548
BIF 2997.982153
BMD 1
BND 1.283978
BOB 12.019192
BRL 5.504904
BSD 1.002018
BTN 94.051388
BWP 13.802968
BYN 3.000673
BYR 19600
BZD 2.015246
CAD 1.41125
CDF 2320.000362
CHF 0.820469
CLF 0.024951
CLP 981.982871
CNY 6.676504
CNH 6.670804
COP 3236.357114
CRC 454.419084
CUC 1
CUP 24.048249
CVE 98.887942
CZK 21.83445
DJF 178.43146
DKK 6.708504
DOP 60.885162
DZD 136.261154
EGP 53.769786
ERN 15
ETB 164.454778
EUR 0.896804
FJD 2.265604
FKP 0.7479
GBP 0.748083
GEL 2.59504
GGP 0.7479
GHS 11.707995
GIP 0.7479
GMD 74.503851
GNF 8874.938344
GTQ 7.657056
GYD 210.062329
HKD 7.84204
HNL 26.930631
HRK 6.76901
HTG 131.321465
HUF 326.000354
IDR 18108.5
ILS 3.18593
IMP 0.7479
INR 93.910504
IQD 1519.035021
IRR 1891353.000352
ISK 122.790386
JEP 0.7479
JMD 159.024259
JOD 0.70904
JPY 158.47504
KES 130.209408
KGS 87.447804
KHR 4082.328147
KMF 442.00035
KPW 899.999961
KRW 1363.803789
KWD 0.31098
KYD 0.83512
KZT 449.127842
LAK 22542.486884
LBP 89728.711717
LKR 333.213757
LRD 170.342137
LSL 16.570826
LTL 2.95274
LVL 0.60489
LYD 6.412269
MAD 9.794718
MDL 17.910408
MGA 4553.159051
MKD 55.203803
MMK 2099.697346
MNT 3600.739032
MOP 8.088606
MRU 40.453791
MUR 47.030378
MVR 15.403739
MWK 1737.500561
MXN 18.62354
MYR 4.061504
MZN 63.903729
NAD 16.570826
NGN 1347.210377
NIO 36.87727
NOK 9.459904
NPR 150.482041
NZD 1.807175
OMR 0.384144
PAB 1.002108
PEN 3.451773
PGK 4.566611
PHP 63.108038
PKR 277.126855
PLN 3.94555
PYG 6263.39626
QAR 3.662795
RON 4.792204
RSD 105.484059
RUB 81.925564
RWF 1478.947132
SAR 3.756342
SBD 8.048583
SCR 13.773553
SDG 601.503676
SEK 9.894504
SGD 1.282704
SHP 0.748923
SLE 22.950371
SLL 20969.504398
SOS 572.620062
SRD 37.583504
STD 20697.981008
STN 21.972109
SVC 8.76732
SYP 13001.999685
SZL 16.565176
THB 33.550369
TJS 9.243442
TMT 3.5
TND 2.998341
TOP 2.40776
TRY 50.141304
TTD 6.795211
TWD 32.775304
TZS 2647.773642
UAH 45.39348
UGX 4098.470921
UYU 40.312094
UZS 11956.414511
VES 896.316404
VND 25582.5
VUV 119.504303
WST 2.787821
XAF 588.264929
XAG 0.019249
XAU 0.00024594347
XCD 2.70255
XCG 1.805838
XDR 0.707052
XOF 588.264929
XPF 106.954845
YER 236.625037
ZAR 16.51943
ZMK 9001.203584
ZMW 20.360522
ZWL 321.999592
SSP 5745.505339
MXV 2.095222
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Frenchman rewarded for lifetime of research into narcolepsy
Frenchman rewarded for lifetime of research into narcolepsy / Photo: © AFP

Frenchman rewarded for lifetime of research into narcolepsy

Emmanuel Mignot is one of the world's leading experts on narcolepsy, a sleep disorder that he finds both "strange" and "fascinating."

Text size:

The French-born Mignot has dedicated his life to studying the causes of narcolepsy and shedding light on one of the great biological mysteries -- sleep.

His discovery of the genetic and molecular causes of the disorder led to his receiving a prestigious Breakthrough Prize on Thursday along with Japan's Masashi Yanagisawa, who made related findings around the same time.

Because of their discoveries, new treatments for narcolepsy -- which causes people to suddenly fall asleep -- and other sleep disorders are being developed.

About one in every 2,000 people suffers from narcolepsy. Some may experience catalepsy -- a sudden trance-like state.

"I am quite proud because what I have discovered is making an enormous difference for my patients," Mignot said in a telephone interview with AFP. "It's the best reward that one could receive."

The 63-year-old Mignot is a sleep researcher at Stanford University in California.

Thirty years ago, when he was a medical student, Mignot fulfilled his military service requirements in France by coming to Stanford to study a French-made drug that was being used to treat narcolepsy.

At the time, he said, the disease was "virtually unknown" and no one was actively studying it.

He became "completely fascinated."

"I told myself it's incredible, this disease, people fall asleep all the time, we have no idea why, and if we could discover the cause we might understand something new about sleep."

Stanford was already home to a renowned sleep center and its laboratory housed narcoleptic dogs, which Mignot began studying in an effort to find a genetic cause of the disease.

Genome sequencing was very primitive at that time and "everybody told me I was crazy," said Mignot, who currently has an adopted narcoleptic dog called Watson.

"I thought it would take a few years and it ended up taking 10."

In 1999, Mignot found a mutation in the genome of narcoleptic dogs. It was located on membrane receptors in the brain that respond to molecules outside the cell, similar to a lock and a key.

- 'Remake a key' -

The Japanese scientist Yanagisawa, meanwhile, had been studying orphan receptors -- receptors of unknown function -- in mice.

He discovered that a molecule that he named orexin binds to the same receptor Mignot detected as abnormal in dogs.

Mice who were deprived of orexin developed narcolepsy.

Mignot immediately began research on human subjects and found that orexin levels in the brain of narcolepsy patients were zero.

Normally, the molecule is produced in great quantities during the day, especially in the evening, allowing one to fight fatigue.

"You don't make a discovery like this twice in your life," Mignot said. "We found the cause of a disease.

"The advantage, is that we can remake a key," he said, referring to orexin.

For the moment, most patients are treated with a combination of powerful sedatives to help them sleep more soundly and amphetamines to keep them awake during the day.

Mignot said tests using a drug that mimics orexin have been "really miraculous."

Patients are fully awake and "transformed."

The challenge is to develop the right dose to be delivered at the right time.

Several companies, including Takeda of Japan, are working on it, and drugs could be authorized in the next few years.

They could be applied to other patients -- people suffering from depression, for example -- who have difficulty waking up, or to those in a coma.

Mignot meanwhile is studying whether narcolepsy may be caused by a flu virus.

The body's immune system may be confusing a flu virus with the cells that produce orexin and T-cells that fight infection are attacking them as a result.

"I've become interested in how the immune system works in the brain," a field he said is "beginning to explode."

As for sleep, Mignot remains fascinated by it even if he has uncovered one of the great mysteries.

"What is it that sleep does that it is so important that we have to do it every day?" he asked. "It's true that we still don't know."

T.Harrison--TFWP